TSRO - Tesaro, Inc.
| Previous Close | 52.21 |
| Open | 52.33 |
| Bid | 51.58 x 100 |
| Ask | 54.68 x 100 |
| Day's Range | 51.25 - 53.07 |
| 52 Week Range | 50.67 - 168.92 |
| Volume | 609,519 |
| Avg. Volume | 1,084,398 |
| Market Cap | 2.827B |
| Beta | 1.34 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Investor's Business Daily•4 days ago
Can This Smaller Biotech Actually Rival Merck, Bristol In Cancer Drugs?
Tesaro popped Monday after unveiling early data for a potential competitor to drugs from Dow Jones component Merck and Bristol.
- Investopedia•9 days ago
3 Biotech Stocks Analysts Have Been Too Bullish On
Regeneron, Incyte and Tesaro have all had a terrible start to 2018, with shares down 14% or more.
Markit•10 days agoSee what the IHS Markit Score report has to say about TESARO Inc.
Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. Over the last month, ETFs holding TSRO are favorable, with net inflows of $5.12 billion.
- Thomson Reuters StreetEvents•11 days ago
Edited Transcript of TSRO presentation 6-Mar-17 1:40pm GMT
TESARO Inc at Raymond James Institutional Investors Conference
- Motley Fool•24 days ago
Tesaro Wants a Stronger Grip in Ovarian Cancer
Management revealed data this week that could help the company against its competitors.
- Investor's Business Daily•24 days ago
Tesaro Sinks After Unveiling Results Of Merck-Tied Ovarian Cancer Study
Analysts were split Tuesday on the results of a study combining drugs from Tesaro and Merck in ovarian cancer.
- Benzinga•25 days ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Eclipse Resources Corp (NYSE: ECR ) stock was trading ...
Markit•last monthSee what the IHS Markit Score report has to say about TESARO Inc.
TESARO Inc NASDAQ/NGS:TSRO
- Motley Fool•last month
AstraZeneca Goes Up Against 2 Cancer Upstarts
Tesaro and Clovis Oncology hope to unseat the big pharma giant, but they've got their work cut out for them.
- Thomson Reuters StreetEvents•last month
Edited Transcript of TSRO earnings conference call or presentation 27-Feb-18 9:15pm GMT
Q4 2017 TESARO Inc Earnings Call
- GuruFocus.com•2 months ago
Tesaro Inc (TSRO) CEO Leon O Jr Moulder Bought $284,650 of Shares
CEO of Tesaro Inc (NASDAQ:TSRO) Leon O Jr Moulder bought 5,000 shares of TSRO on 03/02/2018 at an average price of $56.93 a share.
- Market Realist•2 months ago
AstraZeneca’s Lynparza Witnessed High Growth in 2017
An In-Depth Look into AstraZeneca's 4Q17 Performance
- GuruFocus.com•2 months ago
Tesaro Inc (TSRO) Files 10-K for the Fiscal Year Ended on December 31, 2017
Tesaro Inc (NASDAQ:TSRO) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.
- Investor's Business Daily•2 months ago
Tesaro Dives As Biggest Moneymaker Lags And Another Drug Is Canned
Tesaro crashed to a two-year low Wednesday after its biggest moneymaker fell short in the fourth quarter.
- Motley Fool•2 months ago
Here's Why Tesaro Inc. Stock Dipped Today
A revenue miss suggests competitive pressure will be stronger than expected.
- Zacks•2 months ago
Is the Options Market Predicting a Spike in TESARO (TSRO) Stock?
Investors in TESARO (TSRO) need to pay close attention to the stock based on moves in the options market lately.
- MarketWatch•2 months ago
Tesaro shares plummet 9% after Q4 earnings, revenue misses
Tesaro Inc. shares dropped 9.2% in premarket trade Wednesday after the company reported fourth-quarter earnings and revenue misses. Tesaro reported a loss of $186.1 million, or a loss of $3.35 per share, ...
- Investor's Business Daily•2 months ago
Tesaro Dives 10% After Biggest Cancer Drug Lags Expectations, Guidance
Tesaro reported adjusted losses of $3.35 per share on $48 million in sales for the fourth quarter.
- Investor's Business Daily•2 months ago
These Biotechs Diverge After Biggest Moneymakers Lag Expectations
Exelixis and Clovis shares diverged Tuesday after each reported lackluster sales of their biggest cancer drugs in the fourth quarter.
Markit•2 months agoSee what the IHS Markit Score report has to say about TESARO Inc.
Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. ETFs that hold TSRO had net inflows of $824 million over the last one-month.
Markit•2 months agoSee what the IHS Markit Score report has to say about TESARO Inc.
Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. Over the last one-month, outflows of investor capital in ETFs holding TSRO totaled $15 million.
- Investopedia•2 months ago
3 Biotech Stocks Facing Steep Declines
Regeneron, Alnylam, and Tesaro are all flailing, and these biotech stocks could continue to struggle in the near term.
Markit•2 months agoSee what the IHS Markit Score report has to say about TESARO Inc.
Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. ETFs that hold TSRO had net inflows of $342 million over the last one-month.
Markit•3 months agoSee what the IHS Markit Score report has to say about TESARO Inc.
Short interest is high for TSRO with between 15 and 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting TSRO. Over the last one-month, outflows of investor capital in ETFs holding TSRO totaled $246 million.
- Benzinga•3 months ago
Benzinga Pro's 5 Stocks To Watch Today
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! BlackBerry Ltd (NYSE: BB ) gained nearly 5 percent ...
